Amryt Shares Trading Higher As EMA Endorses Approval Of Filsuvez In Genetic Skin Disease

• The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has backed the approval of Amryt Pharma Plc's (NASDAQ:AMYT) Filsuvez in the European Union for partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients six months and older.  
• The CHMP positive opinion is supported by Phase 3 data from the EASE trial.
• EB is a rare hereditary disorder of the skin, mucous membranes, and internal epithelial linings characterized by extreme skin fragility and blister development.
• Read Next: Amryt Posts Long-Term Safety, Efficacy Mycapssa Data In Acromegaly Patients.
• As a result of the CHMP's positive opinion, the EMA Contingent Value Right issued to Amryt shareholders and option holders before acquiring Aegerion will now become payable.
• Price Action: AMYT shares are trading 8.27% higher at $8.38 during the market session on the last check Friday.